EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Clinical trials for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) explained in plain language.
Never miss a new study
Get alerted when new EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) trials appear
Sign up with your email to follow new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for rare, aggressive cancer
Disease control Recruiting nowThis study tests a combination of three drugs (chidamide, sintilimab, and bevacizumab) in people with advanced extrapulmonary neuroendocrine carcinoma whose cancer has worsened after standard first treatment. The goal is to see if this combination can shrink tumors. About 34 adul…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New radiation therapy targets tough lung cancers in early trial
Disease control Recruiting nowThis study tests a new drug that delivers radiation directly to cancer cells with a protein called DLL3, found in small cell lung cancer and similar tumors. About 138 adults with advanced cancer that has not responded to standard treatments will receive the drug to check safety, …
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Phase: PHASE1, PHASE2 • Sponsor: Molecular Partners AG • Aim: Disease control
Last updated May 18, 2026 12:11 UTC
-
New drug targets hard-to-treat neuroendocrine cancers in early trial
Disease control Recruiting nowThis study tests a new drug, peluntamig, in people with advanced neuroendocrine cancers (like small cell lung cancer) that have a specific marker called DLL3. The trial has two parts: first finding the safest dose, then testing it alone or with chemotherapy. About 203 participant…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated May 01, 2026 16:00 UTC